fda approves semaglutide weight-loss drug Wegovy to reduce heart-disease risks FDA Approves First GLP-1 Weight

Ask your provider for a syringe size that makes your dose easy to identify

Escalation: If tolerated, the dose is increased to the next level (e.g., 7 mg, then 14 mg) every 4 weeks

This function is defective in type 2 diabetes [7,8,9], presumably because DPP-4 activity is enhanced in patients with glucose intolerance [9,10,11]

On the other hand, FDA-approved medications like Wegovy and Zepbound offer a proven path to weight loss with significantly lower risks

Providing adolescents with obesity another option Wegovy is the only once-weekly injectable GLP-1 RA indicated to reduce excess body weight and maintain weight reduction long term in combination with diet and exercise in adolescents with obesity aged 12 years and older 3 The safety and effectiveness of Wegovy injection have not been established in pediatric patients to reduce the risk of major adverse CV events or to reduce excess body weight and maintain weight reduction long term in those less than 12 years of age